Discover
DRTS
Alpha Tau Medical Ltd.
13.06
2 x 9.21
2 x 16.48
bid
ask
-
0.17
1.28%
2 @ 04:00 PM
13.01 -0.05 (0.38%)
| Ytd | 163.84% | |
| 1y | 223.27% |
12.74
day range
13.14
3.43
52 week range
15.79
| Open | 12.85 | Prev Close | 13.23 | Low | 12.74 | High | 13.14 | Mkt Cap | 1.21B |
| Vol | 475.22K | Avg Vol | 526.29K | EPS | -1.04 | P/E | N/A | Forward P/E | -24.27 |
| Beta | 1.22 | Short Ratio | 7.22 | Inst. Own | 9.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-19 | 50-d Avg | 14.29 | 200-d Avg | 10.57 | 1yr Est | 17.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-19 | 2026-09 | -0.14 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.14 | -0.5 | -0.36 | -254.91% |
| 2026-05-18 | 2026-03 | -0.13 | -0.26 | -0.13 | -100.00% |
| 2026-03-09 | 2025-12 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-11-20 | 2025-09 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-08-11 | 2025-06 | -0.12 | -0.13 | -0.01 | -8.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-09-03 | Barclays | Upgrade | Overweight | Overweight |
| 2026-08-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-20 | LEVY RAPHI | Chief Financial Officer | 90.18K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Gem Investment Advisors, LLC | 1.43M | 18.61M | 2.07% |
| 2026-06-29 | HighTower Advisors, LLC | 874.99K | 11.35M | 1.26% |
| 2026-06-29 | Boothbay Fund Management, LLC | 773.48K | 10.04M | 1.12% |
| 2026-06-29 | Aquamarine Financial (cayman) Ltd | 721.50K | 9.36M | 1.04% |
| 2026-06-29 | Pier Capital, LLC | 691.94K | 8.98M | 1.00% |
| 2026-06-29 | UBS Group AG | 642.26K | 8.33M | 0.93% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-09-29 | iShares Trust-iShares Core MSCI EAFE ETF | 470.95K | 6.11M | 0.68% |
| 2026-09-29 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 217.27K | 2.82M | 0.31% |
| 2026-09-29 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 184.38K | 2.39M | 0.27% |
| 2026-09-29 | RBB Fund, Inc.-Adara Smaller Companies Fund | 134.47K | 1.74M | 0.19% |
| 2026-09-29 | iShares, Inc.-iShares MSCI Israel ETF | 133.30K | 1.73M | 0.19% |
| 2026-07-30 | Dunham Funds-Dunham Small Cap Growth Fund | 71.66K | 929.79K | 0.10% |